Skip to main content

Advertisement

SpringerLink
Log in

Serum levels of c-erbB-2 protein in digestive diseases

  • Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

The clinical significance of the measurement of c-erbB-2 oncogene product was evaluated. The subjects consisted of 404 patients, including 248 with cancer of the digestive organs and 128 with benign digestive diseases. Serum c-rebB-2 protein levels were measured by sandwich immunoenzyme assay. The positive rates of c-erbB-2 protein, at a cut-off value of 17.0 U/ml, were, for cancers: hepatocellular carcinoma 61.6%, biliary tract cancer 54.8%, pancreatic cancer 25.0%, esophageal cancer 33.3%, gastric cancer 16.9%, and colorectal cancer 5.0%. For benign digestive diseases, the rates were: liver cirrhosis 63.3%, chronic hepatitis 43.2%, acute hepatitis 42.9%, other liver diseases 42.8%, cholelithiasis 30.0%, and chronic pancreatitis 0%. Serum c-erbB-2 protein levels were significantly correlated with the markers of hepatic functional reserve, the indocyanine green retention rate and the hepaplastin test. These findings suggest that serum c-erbB-2 protein levels are greatly influenced by liver dysfunction and that their clinical usefulness as a serum tumor marker is questionable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986;319:230–234.

    Article  CAS  PubMed  Google Scholar 

  2. Zhou D, Battifora H, Yokota J, et al. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 1987;47:6123–6125.

    CAS  PubMed  Google Scholar 

  3. Kallioniemi O-P, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer. Int J Cancer 1991;49:650–655.

    CAS  PubMed  Google Scholar 

  4. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity forerbB-2 protein as a marker of poor shortterm prognosis in gastric cancer. Cancer Res 1991;51:1034–1038.

    CAS  PubMed  Google Scholar 

  5. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 1989;49:2087–2090.

    CAS  PubMed  Google Scholar 

  6. Yonemura Y, Ninomiya I, Ooyama S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma: Immunoreactivity for c-erbB-2 protein is an independent indicator of poor shortterm prognosis in patients with gastric carcinoma. Cancer 1991;67:2914–2918.

    CAS  PubMed  Google Scholar 

  7. Mori S, Mori Y, Mukaiyama T, et al. In vitro and in vivo release of solubleerbB-2 protein from human carcinoma cells. Jpn J Cancer Res 1990;81:489–494.

    CAS  PubMed  Google Scholar 

  8. Carney WP, Hamer PJ, Petit D, et al. Detection and quantitation of the humanneu oncoprotein. Tumor Marker Oncol 1991;6:53–72.

    Google Scholar 

  9. Ohuchi N, Abe M, Harada Y, et al. Serum levels of c-erbB-2 protein in patients with breast cancer (in Japanese). J Jpn Surg Soc 1991;92:1530.

    CAS  Google Scholar 

  10. Leitzel K, Teramoto Y, Sampson E, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436–1443.

    CAS  PubMed  Google Scholar 

  11. Yu FZ, Sugano K, Ohkura H, Mori S. Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma (in Japanese). Jpn J Clin Pathol 1991;39:1087–1092.

    CAS  Google Scholar 

  12. Narita T, Funahashi H, Satoh Y, Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97–102.

    Article  Google Scholar 

  13. Nakai M, Yonemura Y, Tsugawa K, et al. Expression of soluble c-erbB-2 protein in serum of gastric cancer patients: Preliminary report (in Japanese). J Jpn Surg Soc 1992;93:337.

    CAS  Google Scholar 

  14. Langton BC, Crenshaw MC, Chao LA, et al. An antigen immunologically related to the external domain of gp 185 is shed from nude mouse tumors overexpressing c-erbB-2 (HER-2/neu). Cancer Res 1991;51:2593–2598.

    CAS  PubMed  Google Scholar 

  15. Yamashiki M, Kosaka Y, Tsujimura J, et al. Serum c-erbB-2 levels in healthy adults (in Japanese). Kiso To Rinsho (Clin Report) 1992;26:385–388.

    Google Scholar 

  16. McCann A, Dervan PA, Johnston PA, et al. c-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990;65:88–92.

    CAS  PubMed  Google Scholar 

  17. Collier JD, Guo K, Mathew J, et al. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol 1992;14:377–380.

    Article  CAS  PubMed  Google Scholar 

  18. Marshall JS, Green AM, Pensky J, et al. Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. J Clin Invest 1974;54:555–562.

    CAS  PubMed  Google Scholar 

  19. Stockert RJ, Becker FF. Diminished hepatic binding protein for desialylated glycoproteins during chemical hepatocarcinogenesis. Cancer Res 1980;40:3632–3637.

    CAS  PubMed  Google Scholar 

  20. Sawamura T, Kawasato S, Shiozaki Y, et al. Decrease of a hepatic binding protein specific for asialoglycoprotein with accumulation of serum asialoglycoproteins in galactosamine-treated rats. Gastroenterology 1981;81:527–534.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cancer Research Institute, Kanazawa University, 4-86 Yoneizumi, 921, Kanazawa, Japan

    Yoshiharu Motoo, Norio Sawabu, Yasushi Yamaguchi, Ikurou Mouri, Osamu Yamakawa, Hiroyuki Watanabe, Hideki Ohia & Takashi Okai

  2. Department of Internal Medicine, Kurobe City Hospital, 1108-1 Mikkaichi, 938, Kurobe, Japan

    Hiroshi Makino

Authors
  1. Yoshiharu Motoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norio Sawabu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ikurou Mouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Osamu Yamakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyuki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideki Ohia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Okai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroshi Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Motoo, Y., Sawabu, N., Yamaguchi, Y. et al. Serum levels of c-erbB-2 protein in digestive diseases. J Gastroenterol 29, 616–620 (1994). https://doi.org/10.1007/BF02365445

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02365445

Key words

Search

Navigation